European Medicines Agency nominates Guido Rasi as new head; sets up geriatric expert group

10 June 2011

The European Medicines Agency’s management board has nominated Guido Rasi as new Executive Director of the Agency. Mr Rasi has been Director General of the Italian Medicines Agency since 2008, and a member of the EMA’s management board since 2010.

Before formally taking up his duties, he must appear before the European Parliament. He has been invited to a hearing in front of the European Parliament Committee on Environment, Public Health and Food Safety on July 13. The Board will officially appoint the new Executive Director following his hearing and a positive response from the Parliament. Andreas Pott will continue his role as Acting Executive Director until Mr Rasi takes office.

Mr Rasi holds a Degree in medicine and surgery, with specialization in internal medicine, allergology and clinical immunology from the University of Rome. He worked from 1990 to 2008 in research at the Institute for Experimental Medicine of the National Research Council in Rome, directing the molecular medicine section from 2002 to 2005 and the Tor Vegata section from 2005 to 2008. He was made full professor of microbiology at the University of Rome (Tor Vegata) in 2008.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical